- Conditions
- Immunoglobulin A Nephropathy, IgAN
- Interventions
- Ravulizumab, Placebo
- Drug
- Lead sponsor
- Alexion Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 584 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2030
- U.S. locations
- 39
- States / cities
- Alabaster, Alabama • Phoenix, Arizona • Los Angeles, California + 30 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 457–480
of 7,852
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Carcinoma, Recurrent Non-Small Cell Lung Carcinoma, Recurrent Renal Cell Carcinoma, Recurrent Skin Carcinoma, Stage III Renal Cell Cancer, Stage IIIA Cutaneous Melanoma AJCC v7, Stage IIIA Non-Small Cell Lung Cancer AJCC v7, Stage IIIB Cutaneous Melanoma AJCC v7, Stage IIIB Non-Small Cell Lung Cancer AJCC v7, Stage IIIC Cutaneous Melanoma AJCC v7, Stage IV Cutaneous Melanoma AJCC v6 and v7, Stage IV Non-Small Cell Lung Cancer AJCC v7, Stage IV Renal Cell Cancer
- Interventions
- Laboratory Biomarker Analysis, Pharmacological Study, Recombinant Human Interleukin-15
- Other · Biological
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 19 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 5
- States / cities
- Palo Alto, California • Bethesda, Maryland • Minneapolis, Minnesota + 2 more
- Conditions
- Clostridium Difficile
- Interventions
- Not listed
- Lead sponsor
- University of Minnesota
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 132 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 4
- States / cities
- Minneapolis, Minnesota • Rochester, Minnesota • Philadelphia, Pennsylvania + 1 more
- Conditions
- Acute Myocarditis
- Interventions
- CardiolRx
- Drug
- Lead sponsor
- Cardiol Therapeutics Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 109 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 6
- States / cities
- Washington D.C., District of Columbia • Boston, Massachusetts • Minneapolis, Minnesota + 3 more
- Conditions
- Lymphoma
- Interventions
- Doxorubicin, Bleomycin, Vinblastine, Dacarbazine, Vincristine, Mechlorethamine, Etoposide, Prednisone, Cyclophosphamide, Radiotherapy
- Drug · Radiation
- Lead sponsor
- Eastern Cooperative Oncology Group
- Network
- Eligibility
- 16 Years and older
- Enrollment
- 854 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1999 – 2016
- U.S. locations
- 517
- States / cities
- Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 329 more
- Conditions
- Community Acquired Pneumonia
- Interventions
- lefamulin, Moxifloxacin, Linezolid
- Drug
- Lead sponsor
- Nabriva Therapeutics AG
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 551 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 7
- States / cities
- Hazard, Kentucky • Shreveport, Louisiana • Minneapolis, Minnesota + 4 more
- Conditions
- Overweight, Obesity
- Interventions
- Lifestyle modification
- Behavioral
- Lead sponsor
- University of Minnesota
- Other
- Eligibility
- 8 Years to 16 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011 – 2012
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Kidney Transplantation
- Interventions
- Tacrolimus Modified Release (MR), tacrolimus
- Drug
- Lead sponsor
- Astellas Pharma Inc
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2008
- U.S. locations
- 7
- States / cities
- San Diego, California • Miami, Florida • Minneapolis, Minnesota + 4 more
- Conditions
- Seasonal Allergic Rhinitis
- Interventions
- Placebo, azelastineHcl, fluticasone propionate, azelastine Hcl/fluticasone propionate
- Drug
- Lead sponsor
- Meda Pharmaceuticals
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 1,791 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009
- U.S. locations
- 45
- States / cities
- Scottsdale, Arizona • Encinitas, California • Fountain Valley, California + 35 more
- Conditions
- Anterior Cruciate Ligament Injury, Anterior Cruciate Ligament Reconstruction, Joint Instability
- Interventions
- Anterior cruciate ligament reconstruction (ACLR), Lateral extra-articular tenodesis (LET)
- Procedure
- Lead sponsor
- University of Pittsburgh
- Other
- Eligibility
- 14 Years to 25 Years
- Enrollment
- 1,272 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2028
- U.S. locations
- 14
- States / cities
- Redwood City, California • San Francisco, California • Orlando, Florida + 11 more
- Conditions
- Functioning Pancreatic Neuroendocrine Tumor, Intermediate Grade Lung Neuroendocrine Neoplasm, Locally Advanced Digestive System Neuroendocrine Neoplasm, Locally Advanced Digestive System Neuroendocrine Tumor G1, Locally Advanced Lung Neuroendocrine Neoplasm, Locally Advanced Pancreatic Neuroendocrine Tumor, Locally Advanced Unresectable Digestive System Neuroendocrine Neoplasm, Low Grade Lung Neuroendocrine Neoplasm, Lung Neuroendocrine Tumor, Lung Neuroendocrine Tumor G2, Metastatic Digestive System Neuroendocrine Neoplasm, Metastatic Digestive System Neuroendocrine Tumor G1, Metastatic Lung Neuroendocrine Neoplasm, Metastatic Lung Neuroendocrine Tumor, Metastatic Pancreatic Neuroendocrine Neoplasm, Metastatic Pancreatic Neuroendocrine Tumor, Metastatic Thymus Neuroendocrine Neoplasm, Neuroendocrine Neoplasm, Neuroendocrine Tumor, Neuroendocrine Tumor G2, Non-Functioning Pancreatic Neuroendocrine Tumor, Pancreatic Serotonin-Producing Neuroendocrine Tumor, Thymus Neuroendocrine Tumor, Unresectable Digestive System Neuroendocrine Neoplasm, Unresectable Digestive System Neuroendocrine Tumor G1, Unresectable Lung Neuroendocrine Neoplasm, Unresectable Pancreatic Neuroendocrine Neoplasm, Unresectable Thymus Neuroendocrine Neoplasm
- Interventions
- Biospecimen Collection, Cabozantinib S-malate, Computed Tomography, Magnetic Resonance Imaging, Placebo Administration, Quality-of-Life Assessment, X-Ray Imaging
- Procedure · Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 298 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2027
- U.S. locations
- 432
- States / cities
- Anchorage, Alaska • Kingman, Arizona • Phoenix, Arizona + 289 more
- Conditions
- Congestive Heart Failure
- Interventions
- Ad5.hAC6, Sucrose (3%)
- Drug
- Lead sponsor
- Hammond, H. Kirk, M.D.
- Individual
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 56 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2017
- U.S. locations
- 7
- States / cities
- San Diego, California • Chicago, Illinois • Minneapolis, Minnesota + 3 more
- Conditions
- Graft Versus Host Disease
- Interventions
- cyclosporine, hydroxychloroquine, prednisone, tacrolimus
- Drug
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- 1 Year to 29 Years
- Enrollment
- 82 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2011
- U.S. locations
- 89
- States / cities
- Tucson, Arizona • Little Rock, Arkansas • Downey, California + 67 more
- Conditions
- Alcohol Intoxication
- Interventions
- Not listed
- Lead sponsor
- Hennepin Healthcare Research Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 668 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2021
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Parkinson's Disease Psychosis
- Interventions
- Pimavanserin, Quetiapine
- Drug
- Lead sponsor
- VA Office of Research and Development
- Federal
- Eligibility
- 40 Years and older
- Enrollment
- 358 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2028
- U.S. locations
- 24
- States / cities
- Tucson, Arizona • Loma Linda, California • Palo Alto, California + 20 more
- Conditions
- Colorectal Cancer
- Interventions
- Telisotuzumab Adizutecan, Standard of Care
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 140 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 22
- States / cities
- Huntsville, Alabama • Fullerton, California • Los Angeles, California + 18 more
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- SK-0403
- Drug
- Lead sponsor
- Kowa Research Institute, Inc.
- Industry
- Eligibility
- 18 Years to 79 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2010
- U.S. locations
- 2
- States / cities
- Orlando, Florida • Minneapolis, Minnesota
- Conditions
- Skin/Soft Tissue Infections, Methicillin Resistant Staphylococcus Aureus (MRSA)
- Interventions
- linezolid, vancomycin
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,077 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2007
- U.S. locations
- 76
- States / cities
- Montgomery, Alabama • Tucson, Arizona • Los Angeles, California + 53 more
- Conditions
- Stroke
- Interventions
- Sentinel® Cerebral Protection System
- Device
- Lead sponsor
- Boston Scientific Corporation
- Industry
- Eligibility
- Not listed
- Enrollment
- 3,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 41
- States / cities
- Tucson, Arizona • Los Angeles, California • Sacramento, California + 37 more
- Conditions
- Advanced Melanoma
- Interventions
- Tebentafusp, Tebentafusp with Pembrolizumab, Investigators Choice
- Drug
- Lead sponsor
- Immunocore Ltd
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 540 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2028
- U.S. locations
- 25
- States / cities
- Phoenix, Arizona • Jacksonville, Florida • Orlando, Florida + 19 more
- Conditions
- Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
- Interventions
- Selpercatinib
- Drug
- Lead sponsor
- SWOG Cancer Research Network
- Network
- Eligibility
- Not listed
- Enrollment
- 124 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2026
- U.S. locations
- 306
- States / cities
- Fairbanks, Alaska • Little Rock, Arkansas • Anaheim, California + 251 more
- Conditions
- Renal Impairment, Healthy
- Interventions
- Sotagliflozin
- Drug
- Lead sponsor
- Lexicon Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2017
- U.S. locations
- 4
- States / cities
- Miami, Florida • Orlando, Florida • Minneapolis, Minnesota + 1 more
- Conditions
- Non-Small Cell Lung Carcinoma
- Interventions
- Motexafin gadolinium and pemetrexed
- Drug
- Lead sponsor
- Pharmacyclics LLC.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 74 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2008
- U.S. locations
- 11
- States / cities
- Huntington Beach, California • Long Beach, California • Chicago, Illinois + 8 more
- Conditions
- Hypertension Pulmonary Secondary, Heart Failure, Right Sided, Heart Failure With Normal Ejection Fraction
- Interventions
- Levosimendan, Matching Placebo
- Drug
- Lead sponsor
- Tenax Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 44 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 16
- States / cities
- Stanford, California • Chicago, Illinois • Boston, Massachusetts + 10 more